Pravastatin counteracts angiotensin II-induced upregulation and activation of nadph oxidase at plasma membrane of human endothelial cells

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 2, 2010, Pages 203-212

  Alvarez, Ezequiel ^a   Rodiño Janeiro, Bruno K ^a   Ucieda Somoza, Rafael ^b   González Juanatey, José R ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Angiotensin II; Human endothelial cells; NADPH oxidase; Pravastatin; Reactive oxygen species

Indexed keywords

ANGIOTENSIN II; MEMBRANE PROTEIN; PRAVASTATIN; PROTEIN P22PHOX; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SUPEROXIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; UMBILICAL VEIN; UPREGULATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CULTURE; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II; CELL MEMBRANE; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; HUMANS; NADPH OXIDASE; PRAVASTATIN; UP-REGULATION;

EID: 77649291952     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181ce5f5a     Document Type: Article

References (35)

1. Munzel T, Sinning C, Post F, et al. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med. 2008;40: 180-196.
2. Wolin MS. Interactions of oxidants with vascular signaling systems. Arterioscler Thromb Vasc Biol. 2000;20:1430-1442.
3. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 2003;285:R277-R297.
4. Yokoyama M, Inoue N. How vascular NAD(P)H oxidase activity and nox isoform expression are regulated. Arterioscler Thromb Vasc Biol. 2004; 24:1540-1541.
5. Alom-Ruiz SP, Anilkumar N, Shah AM. Reactive oxygen species and endothelial activation. Antioxid Redox Signal. 2008;10:1089-1100.
6. Harrison DG, Cai H, Landmesser U, et al. Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2003;4:51-61.
7. Zhang H, Schmeisser A, Garlichs CD, et al. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: Role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res. 1999;44: 215-222.
8. Sohn HY, Raff U, Hoffmann A, et al. Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br J Pharmacol. 2000;131:667-672.
9. Li JM, Shah AM. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J Biol Chem. 2003;278:12094-12100.
10. Girouard H, Park L, Anrather J, et al. Angiotensin II attenuates endotheliumdependent responses in the cerebral microcirculation through nox-2-derived radicals. Arterioscler Thromb Vasc Biol. 2006;26:826-832.
11. Didion SP, Faraci FM. Angiotensin II produces superoxide-mediated impairment of endothelial function in cerebral arterioles. Stroke. 2003;34: 2038-2042.
12. II M, Losordo DW. Statins and the endothelium. Vascul Pharmacol. 2007; 46:1-9.
13. Martinez-Gonzalez J, Badimon L. Influence of statin use on endothelial function: from bench to clinics. Curr Pharm Des. 2007;13: 1771-1786.
14. Vecchione C, Gentile MT, Aretini A, et al. A novel mechanism of action for statins against diabetes-induced oxidative stress. Diabetologia. 2007; 50:874-880.
15. Rueckschloss U, Galle J, Holtz J, et al. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: Antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation. 2001;104:1767-1772.
16. Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001; 37:1450-1457.
17. Chlopicki S, Gryglewski RJ. Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium. Pharmacol Rep. 2005; 57(Suppl):86-96.
18. Orallo F, Alvarez E, Camina M, et al. The possible implication of transresveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol Pharmacol. 2002;61:294-302.
19. Bellavite P, Serra MC, Davoli A, et al. The NADPH oxidase of guinea pig polymorphonuclear leucocytes. Properties of the deoxycholate extracted enzyme. Mol Cell Biochem. 1983;52:17-25.
20. Wagner AH, Kohler T, Ruckschloss U, et al. Improvement of nitric oxidedependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61-69.
21. Rikitake Y, Kawashima S, Takeshita S, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 2001;154: 87-96.
22. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22: 300-305.
23. Cai H, Li Z, Dikalov S, et al. NAD(P)H oxidase-derived hydrogen peroxide mediates endothelial nitric oxide production in response to angiotensin II. J Biol Chem. 2002;277:48311-48317.
24. Mollnau H, Wendt M, Szocs K, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res. 2002;90:E58-E65.
25. Rueckschloss U, Quinn MT, Holtz J, et al. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: Protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2002;22:1845-1851.
26. Guzik TJ, West NE, Black E, et al. Vascular superoxide production by NAD(P)H oxidase: Association with endothelial dysfunction and clinical risk factors. Circ Res. 2000;86:E85-E90.
27. Gertzberg N, Neumann P, Rizzo V, et al. NAD(P)H oxidase mediates the endothelial barrier dysfunction induced by TNF-alpha. Am J Physiol Lung Cell Mol Physiol. 2004;286:L37-L48.
28. Ray R, Shah AM. NADPH oxidase and endothelial cell function. Clin Sci (Lond). 2005;109:217-226.
29. Ago T, Kitazono T, Ooboshi H, et al. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation. 2004;109:227-233.
30. Van Buul JD, Fernandez-Borja M, Anthony EC, et al. Expression and localization of NOX2 and NOX4 in primary human endothelial cells. Antioxid Redox Signal. 2005;7:308-317.
31. Inoue I, Goto S, Mizotani K, et al. LipophilicHMG-CoAreductase inhibitor has an anti-inflammatory effect: Reduction of MRNA levels for interleukin- 1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci. 2000;67:863-876.
32. Stoll LL, McCormick ML, Denning GM, et al. Antioxidant effects of statins. Timely Top Med Cardiovasc Dis. 2005;9:E1.
33. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21: 1712-1719.
34. Nauseef WM. Biological roles for the NOX family NADPH oxidases. J Biol Chem. 2008;283:16961-16965.
35. Itoh S, Umemoto S, Hiromoto M, et al. Importance of NAD(P)H oxidasemediated oxidative stress and contractile type smooth muscle myosin heavy chain SM2 at the early stage of atherosclerosis. Circulation. 2002; 105:2288-2295.